Mo, good post and agreed 100%. I believe this is t
Post# of 72440
Quote:
”A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
http://www.ipharminc.com/press-release/2018/1...priorities